Not currently recruiting at UCSF
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Summary
- Eligibility
- for people ages 25-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Peter Ljubenkov, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Peter Ljubenkov, MD
Assistant Professor, Neurology, School of Medicine. Authored (or co-authored) 36 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Alector Inc.
- ID
- NCT04374136
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 180 study participants
- Last Updated